irinotecan has been researched along with Carcinoma, Small Cell in 235 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (14.47) | 18.2507 |
| 2000's | 163 (69.36) | 29.6817 |
| 2010's | 35 (14.89) | 24.3611 |
| 2020's | 3 (1.28) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Z; Zhang, Y | 1 |
| Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M | 1 |
| Hirata, K; Ichikawa, J; Koreeda, N; Noritomi, T; Okamoto, T; Ryu, S; Sannomiya, H; Sato, K; Shin, Y; Yamana, I; Yoshida, T; Yoshida, Y | 1 |
| Coppo, R; Endo, H; Inoue, M; Kakeya, H; Kamiura, S; Kaneko, K; Kimura, T; Kondo, J; Masuda, M; Onuma, K; Tanaka, M; Ueda, Y; Yoshino, K | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y | 1 |
| Jett, JR; Kalemkerian, GP; Kesler, KA; Schild, SE | 1 |
| Funahashi, H; Ishiguro, H; Kimura, M; Matsuo, Y; Miyai, H; Takeyama, H; Wakasugi, T | 1 |
| Harada, M; Hida, T; Imamura, F; Ishikura, S; Kawahara, M; Kubota, K; Matsui, K; Mizusawa, J; Nakagawa, K; Negoro, S; Nishio, M; Okamoto, H; Saijo, N; Sakai, H; Shibata, T; Shinkai, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Arif, Q; Bharti, A; Brand, TM; Dhanasingh, I; Hembrough, T; Husain, AN; Kanteti, R; Nandi, S; Rolle, CE; Salgia, R; Surati, M; Tretiakova, M; Vokes, EE; Wheeler, DL; Yala, S | 1 |
| Hida, N; Horiike, A; Ishii, M; Kenmotsu, H; Misumi, Y; Murakami, H; Nishio, M; Ohyanagi, F; Okamoto, H; Shimokawa, T; Takahashi, T; Yamamoto, N | 1 |
| Hamada, A; Harada, T; Kudoh, S; Maeno, K; Miyawaki, H; Moriyama, A; Nakagawa, K; Nakanishi, Y; Saeki, S; Shimokawa, M; Takayama, K | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Aoyama, T; Hamano, T; Hashimura, T; Kawai, J; Kimura, H; Uegaki, M | 1 |
| Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R | 1 |
| Aoyama, T; Hayashi, S; Hayashi, T; Kanazawa, A; Kunisaki, C; Masuda, M; Oshima, T; Rino, Y; Sato, T; Segami, K; Sugano, N; Yamamoto, N; Yoshikawa, T; Yukawa, H | 1 |
| Barceló-Batllori, S; Berdasco, M; Borck, G; Carneiro, F; de la Torre, C; Esteller, M; Gomez, A; Heyn, H; Iwakawa, R; Kohno, T; Martínez-Cardús, A; Moran, S; Moura, CS; Moutinho, C; Pastorino, U; Pérez-Salvia, M; Roz, L; Savola, S; Setien, F; Simó-Riudalbas, L; Soler, M; Szakszon, K; Vaquero, A; Vidal, A; Vidal, E; Villanueva, A; Yokota, J; Zondervan, I | 1 |
| Kimura, T; Matsuzaki, S; Ogita, K; Sawada, M; Ueda, Y; Yoshida, S; Yoshino, K | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Danbara, N; Horitani, S; Ikeura, T; Kwon, AH; Masuda, M; Miyoshi, H; Nakamaru, K; Okazaki, K; Satoi, S; Takaoka, M; Toyokawa, H; Uemura, Y; Yamada, Y | 1 |
| Motoshita, J; Nakagawa, T; Nakano, T; Nakashima, T; Okabe, M; Shiratsuchi, H; Tamae, A; Tanaka, R; Yasumatsu, R | 1 |
| Abe, N; Abe, S; Aoto, K; Kawana, S; Murakami, F; Ohtake, T; Okano, M; Suzuki, O; Tachibana, K; Takenoshita, S; Tasaki, K | 1 |
| Ando, T; Hirose, Y; Ishikawa, H; Kameyama, H; Katada, T; Kobayashi, T; Miura, K; Ohashi, T; Sakata, J; Soma, D; Takano, K; Takizawa, K; Toge, K; Wakai, T; Yuza, K | 1 |
| Baba, S; Chin, K; Hatake, K; Hosaka, H; Ishiyama, A; Kozuka, T; Mizunuma, N; Seto, Y; Shinozaki, E; Suenaga, M; Yamamoto, N | 1 |
| Oshita, F; Saito, H; Yamada, K | 1 |
| Asagawa, T; Higaki, R; Ishii, H; Itou, M; Kobashi, K; Miyazaki, F; Murakami, M; Ninomiya, H; Noguchi, T; Tsunemitsu, K | 1 |
| Ito, N; Kamba, T; Kamoto, T; Kanematsu, A; Masui, K; Nakamura, E; Nishiyama, H; Ogawa, O; Soda, T; Watanabe, J; Yoshimura, K | 1 |
| Aasebø, U; Bergman, B; Bremnes, R; Ek, L; Fluge, S; Hermes, A; Sederholm, C; Sörenson, S; Sundstrøm, S; Thaning, L; Vilsvik, J | 1 |
| Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuzawa, T; Mishima, H; Nakamori, S; Takeda, M; Tsujinaka, T | 1 |
| Kijima, H; Kusumi, T; Nakamura, M; Nishime, C; Ohnishi, Y; Sato, F; Suemizu, H; Tamaoki, N; Ueyama, Y; Yamazaki, H | 1 |
| Hihara, J; Mizuiri, H; Okada, M | 1 |
| Abdel-Aziz, H; Abdelfatah, A; Abdelwahab, S; Abdulla, H; Azmy, A; Dwedar, I; Margerges, M; Riad, A; Sharma, V | 1 |
| Hirota, M; Ichihara, T; Nakamura, E; Yamashita, K | 1 |
| Izumi, K; Mouri, H; Ohtsubo, K; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K; Zen, Y | 1 |
| Choi, K; Rineer, J; Sanmugarajah, J | 1 |
| Chang, J; Cho, BC; Choi, HJ; Jeong, J; Jung, MK; Kim, JH; Kim, SH; Kim, SK; Lee, YJ; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Cantor, A; Miley, D; Reddy, V; Robert, F; Rossman, J | 1 |
| Gleave, M; Gout, PW; Liu, DM; Tung, WL; Wang, Y | 1 |
| Doi, K; Hirano, Y; Kudoh, K; Ogata, K; Ohchi, T | 1 |
| Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Ando, T; Fujinami, H; Hasumoto, Y; Hosokawa, A; Itaya, Y; Kajiura, S; Miyazaki, T; Nishikawa, J; Ogawa, K; Sugiyama, T; Suzuki, N; Ueda, A; Yamawaki, H | 1 |
| Chen, X; Guo, R; Jin, S; Shu, Y; Sun, J; Wang, T; Xu, B | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Dudek, AZ; Graziano, SL; Green, MR; Hodgson, LD; Pang, HH; Ready, NE; Vokes, EE | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Asakuma, M; Fukui, T; Igawa, S; Katagiri, M; Katono, K; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Sasaki, J; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yokoba, M | 1 |
| Daimon, T; Furuse, K; Kawahara, M; Mio, T; Okishio, K; Yanagihara, K; Yoshioka, H | 1 |
| Iwase, Y; Maitani, Y | 1 |
| Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Nagase, H; Oshima, S; Sakamoto, T | 1 |
| Fukuoka, M; Masuda, N | 2 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Atagi, S; Furuse, K; Hosoe, S; Kawaguchi, T; Kawahara, M; Naka, N; Ogawara, M; Okishio, K; Takemoto, Y; Tsuchiyama, T; Ueno, K | 1 |
| Ichinose, Y | 1 |
| Choy, H; Wu, HG | 1 |
| Bleickardt, E; Kwong, MS; Murren, JR | 1 |
| Sandler, A | 3 |
| Fukuda, M; Ichiki, M; Kawabata, S; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Nakatomi, K; Narasaki, F; Oka, M; Rikimaru, T; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Turrisi, AT | 1 |
| Sandler, AB | 2 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Fukuoka, M; Kudoh, S; Matsui, K; Mori, K; Nakano, T; Negoro, S; Nishiwaki, Y; Noda, K; Ohsaki, Y; Saijo, N; Sekine, I; Yokoyama, A | 1 |
| Ishikawa, H; Kamakari, K; Noguchi, T; Ono, N; Tashima, M; Terada, Y | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noguchi, H; Ogura, K; Ohmori, T | 1 |
| Araya, Y; Fujimoto, T; Inoue, S; Kameyama, M; Kanetoshi, A; Ohtsuka, K; Shida, A; Takaoka, K | 1 |
| Aizawa, H; Fujiki, R; Gohara, R; Ichiki, M; Kitajima, T; Rikimaru, T; Shimada, A | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Natale, RB | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Lee, JJ; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Saijo, N | 2 |
| Ando, M; Gemma, A; Hibino, S; Kobayashi, K; Kudoh, S; Kurimoto, F; Mizutani, H; Moriyama, G; Nara, M; Okano, T; Seike, M; Shibuya, M; Yoshimura, A | 1 |
| Cheong, K; Chrystal, K; Harper, P | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Nakanishi, Y; Uchino, J | 1 |
| Hori, S; Imada, T; Ishiki, K; Ishioka, H; Mizuno, M; Motoi, M; Nagahara, Y; Okamoto, T; Take, S; Yoshida, T | 1 |
| Agelaki, S; Athanasiadis, A; Boukovinas, J; Christophylakis, C; Georgoulias, V; Kouroussis, C; Maltezakis, G; Milaki, G; Pavlakou, G; Syrigos, K; Vardakis, N; Varthalitis, J | 1 |
| Kobayashi, N; Kudo, K; Takeda, Y; Toyota, E; Yonemori, K | 1 |
| Hütter, G; Keilholz, U; Krebs, P; Schmittel, A; Schulze, K; Thiel, E | 1 |
| Horiike, A; Saijo, N | 2 |
| Langer, CJ | 1 |
| Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Chen, A; Chou, R; Lau, D | 1 |
| Cho, KH; Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, JS; Lee, SY | 1 |
| Hasegawa, Y; Hayashi, N; Kato, Y; Wakita, T | 1 |
| Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Negoro, S | 2 |
| Ariyoshi, Y; Fukuda, Y; Fukuoka, M; Isobe, T; Katakami, N; Komuta, K; Kudoh, S; Nakamura, S; Nakano, T; Takada, M; Takada, Y | 1 |
| Imamura, F; Kawahara, M; Kubota, K; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K | 1 |
| Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Park, CG; Yoon, SM | 1 |
| Fujimoto, K; Harada, T; Watanabe, K | 1 |
| Hakuba, N; Hyodo, M; Sato, H; Yokoi, T | 1 |
| Blankenburg, T; Bork, I; Juergens, S; Nagel, S; Schaedlich, S; Schuette, W; Wollschlaeger, B | 1 |
| Kato, T; Masuoka, HO; Sato, K; Tamahashi, N; Yano, H | 1 |
| Greco, FA; Spigel, DR | 1 |
| Glisson, BS; Johnson, FM; Krug, LM; Patel, J; Peeples, B; Prieto, VG; Shoaf, S; Tamboli, P; Tran, HT | 1 |
| Fischer von Weikersthal, L; Hortig, P; Keilholz, U; Martus, P; Reeb, M; Schmittel, A; Schulze, K; Sebastian, M; Thiel, E | 1 |
| Baba, H; Endo, K; Haraguchi, M; Kohnoe, S; Maehara, Y; Nishiyama, K; Okamura, T; Toh, Y | 1 |
| Kawahara, M | 1 |
| Aoe, K; Hotta, K; Kawata, N; Kiura, K; Kozuki, T; Okada, C; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takeyama, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Fujimura, M; Ishiura, Y; Kasahara, K; Nakamura, H; Saito, K; Terasaki, Y; Yokawa, S | 1 |
| Fukuoka, Y; Hasegawa, Y; Hitsuda, Y; Igishi, T; Kodani, M; Kurai, J; Miyata, M; Shimizu, E; Suyama, H; Touge, H; Yasuda, K | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Gandara, DR; Lara, PN; Natale, RB | 1 |
| Ansari, R; Beck, T; Bunn, PA; Byrne, M; Einhorn, L; Ellis, P; Guthrie, T; Hanna, N; Hariharan, S; Langer, C; Morrison, M; Sandler, A; Wang, B | 1 |
| Fournel, P | 1 |
| Pujol, JL | 1 |
| Büscher, C; Fähndrich, S; Fietkau, R; Klautke, G; Semrau, S; Virchow, C | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Kawashima, O; Morishita, Y; Nagashima, T; Sugano, M | 1 |
| Hida, N; Kunikane, H; Naoki, K; Narita, Y; Okamoto, H; Watanabe, K | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| In, KH; Jeong, HC; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Katakami, N | 1 |
| Kamoto, T; Kawahara, T; Nishiyama, H; Ogawa, O; Yamamoto, S | 1 |
| Crawford, J; Dunphy, F; Garst, J; Herndon, JE; Kelley, MJ; Riedel, RF | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SK; Lee, CG; Moon, YW; Shin, SJ; Sohn, JH | 1 |
| Atkins, JN; Green, MR; Herndon, JE; Lee, ME; Mauer, A; Rocha-Lima, CM; Vokes, E | 1 |
| Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K | 1 |
| Ahn, JS; Ahn, MJ; Hong, YS; Hwang, IG; Lee, HR; Lee, J; Lee, SC; Lim, HY; Park, BB; Park, K; Park, S | 1 |
| Arakawa, K; Hamada, K; Kashiwabara, K; Kawate, S; Morishita, Y; Ohwada, S; Sunose, Y; Takeyoshi, I; Tohgo, N; Toya, H; Tsutsumi, H | 1 |
| Ami, K; Ando, M; Ganno, H; Ito, T; Nagahama, T; Ohbu, M; Taira, M | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Funahashi, M; Murayama, T; Yamada, T | 1 |
| Ono, A; Yamamoto, N | 1 |
| Chang, J; Choi, BW; Choi, HJ; Chung, KY; Kim, GE; Kim, JH; Kim, SK; Kim, YS; Lee, CG; Moon, YW; Sohn, JH | 1 |
| Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Berenguer, R; Ferrandini, S; Garberi, J; Politi, P; Trini, E; Valsecchi, M | 1 |
| Yoneda, S | 1 |
| Hamano, R; Hirao, T; Kobayashi, T; Masuzawa, T; Shibata, K; Tokuoka, M | 1 |
| Andritzky, B; Bokemeyer, C; Burkholder, I; Dürk, H; Edler, L; Elbers, M; Engel-Riedel, W; Fischer, J; Görn, M; Gütz, S; Hossfeld, DK; Kortsik, C; Krüll, A; Laack, E; Meissner, C; Müller, T; Schuch, G; Thöm, I | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, M; Ohyanagi, F; Okano, Y; Okumura, S; Satoh, Y | 1 |
| Fujimoto, K; Hirao, Y; Matsushita, C; Miyake, M; Tanaka, M; Tanaka, N | 1 |
| Akerley, W; Atkins, JN; Bearden, JD; Chansky, K; Crowley, JJ; Gandara, DR; Goodwin, JW; Hesketh, PJ; McCoy, J | 1 |
| Hotta, K; Ichimura, K; Kiura, K; Matsuoka, J; Osawa, M; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Goto, T; Kawakami, T; Kikuchi, K; Kitazawa, E; Miyakawa, H; Mizuguchi, K; Murakawa, Y; Nakano, K; Sato, S; Tajima, Y; Takai, A; Watabe, H; Watanabe, M | 1 |
| Fennell, DA; Rudd, RM; Shamash, J; Sheaff, MT; Slater, SE; Stebbing, J; Steele, JP; Wells, P | 1 |
| Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Pectasides, D; Samantas, E; Skarlos, D; Syrigos, K | 1 |
| Bae, SH; Baek, JH; Do, YR; Hur, IK; Hyun, MS; Kim, MK; Kwon, KY; Lee, KH; Lee, WS; Park, KU; Ryoo, HM; Song, HS | 1 |
| Andrews, M; Daniels, L; Dowlati, A; Green, MR; Leff, R; Willey, J; Yellamraju, L | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
| de Jong, WK; de Jonge, MJ; Groen, HJ; van der Leest, AH; van Meerbeeck, JP | 1 |
| Baba, M; Hayashi, N; Kakimoto, Y; Koshiishi, H; Koshiishi, Y; Minami, T; Okamura, T; Takahashi, E; Yasui, T | 1 |
| Isobe, H; Matsui, K; Mori, K; Nakagawa, K; Nishiwaki, Y; Nokihara, H; Saijo, N; Sekine, I; Takeda, K; Tamura, T | 1 |
| An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Hahm, JR; Hwang, IG; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, SH; Lee, GW; Lee, JD; Lee, JS | 1 |
| Chinen, T; Hirayasu, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ogawa, K; Ohta, M; Oshiro, Y; Samura, H; Teruya, J; Teruya, T; Uehara, T; Yohena, T | 1 |
| Chen, A; Chen, G; Fehrenbacher, L; Gandara, D; Huynh, M; Lau, D | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| Jung, SS; Kim, JO; Kim, SY; Lee, JE; Park, HS | 1 |
| Hashimoto, K; Igishi, T; Matsumoto, S; Morita, M; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y; Yamasaki, A | 1 |
| Arakura, N; Hamano, H; Kawa, S; Komatsu, K; Muraki, T; Ozaki, Y; Tanaka, E | 1 |
| Gorbunova, VA; Kuz'minov, AE; Naskhletashvili, DR | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Ettinger, DS | 1 |
| Grant, SC; Kris, MG | 1 |
| Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Takifuji, N; Yoshikawa, A | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 3 |
| Kanzawa, F; Kubota, N; Nishio, K; Saijo, N | 1 |
| Itoh, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Morino, H; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Fujiwara, Y; Ohune, T; Sumiyoshi, H; Tamura, K; Yamakido, M; Yamaoka, N | 1 |
| Fukuoka, M; Masuda, N; Negoro, S | 1 |
| Arioka, H; Bojanowski, K; Fukuda, M; Ishida, T; Kanzawa, F; Nishio, K; Ogasawara, H; Oka, M; Saijo, N | 1 |
| Fujii, T; Hirata, K; Kanazawa, H; Katsumoto, E; Kudoh, S; Kurihara, N; Ohtsuka, T; Okishio, K; Shoji, S; Yoshikawa, J | 1 |
| Fujiwara, Y; Fukuoka, M; Kawase, I; Kudoh, S; Okishio, K; Tada, T; Takada, M; Tamura, K; Yamakido, M; Yamaoka, N | 1 |
| Bessho, A; Chikamori, K; Harada, M; Kimura, I; Kiura, K; Matsushita, A; Ohnoshi, T; Tabata, M; Ueoka, H; Yamane, H | 1 |
| Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A | 1 |
| Murray, N | 1 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Ariyoshi, Y; Fujiwara, Y; Fukuoka, M; Furuse, K; Kinoshita, A; Kudoh, S; Takada, Y; Yamamoto, H | 1 |
| Boven, E; Dingemans, AM; Giaccone, G; Jansen, WJ; Kedde, MA; Pinedo, HM; van Ark-Otte, J; van der Vijgh, WJ | 1 |
| Hirose, T; Machida, S; Mori, K; Tominaga, K | 1 |
| Fukuoka, M; Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Sawaguchi, H; Tada, T; Takeda, K; Takifuji, N; Ushijima, S; Yana, T | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Armand, JP; Couteau, C | 1 |
| Chikamori, K; Gemba, K; Harada, M; Hiraki, S; Kiura, K; Segawa, Y; Shibayama, T; Tabata, M; Ueoka, H; Yonei, T | 1 |
| Hara, N; Inoue, K; Kawasaki, M; Minami, T; Nakanishi, Y; Osaki, S; Takaki, Y; Takano, K; Takayama, K; Wataya, H | 1 |
| Bayliff, S; Rosoff, PM | 1 |
| Kelly, K | 2 |
| Masuda, N | 1 |
| Masuda, N; Negoro, S | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Negoro, S | 1 |
| Rushing, DA | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Fujita, A; Fukuoka, S; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Ohe, Y; Saijo, N | 1 |
| Komura, Y; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S | 1 |
| Fukumoto, H; Kanzawa, F; Koh, Y; Koizumi, F; Nakamura, T; Nishio, K; Saijo, N; Tatsumi, Y; Yoshioka, T | 1 |
| Blum, K; Gallipoli , M; McKeon, A; Murren, JR; Rich, R | 1 |
| Johnson, DH | 1 |
| Fukuoka, M | 2 |
| Tamura, T | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Eriguchi, M; Fujii, Y; Sairenji, T | 1 |
| Fukuoka, M; Kawahara, M; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K; Yamamoto, S; Yokoyama, A | 1 |
| Carney, DN | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Ikeda, T; Minami, H; Saka, H; Sakai, S; Sato, M; Sekido, Y; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Aoe, K; Chikamori, K; Chikamori, M; Harada, M; Kawata, K; Kiura, K; Kohara, H; Matsushita, A; Tabata, M; Ueoka, H | 1 |
| Kato, Y; Saijo, N | 1 |
| Ando, Y; Figg, WD | 1 |
| Kato, H; Tsuboi, M | 1 |
| Sörenson, S | 1 |
| Sakai, H; Yoneda, S | 1 |
| Yokoyama, A | 1 |
| Kubota, K; Yoh, K | 1 |
| Nokihara, H; Ohe, Y | 1 |
| Fukuoka, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Nishioka, M; Takada, M; Takifuji, N | 1 |
| Ariyoshi, Y; Sugiura, T | 1 |
| Pautier, P | 1 |
| Fukuoka, M; Furuse, K; Hara, N; Hasegawa, K; Nakai, H; Nakao, I; Ogura, T; Saito, H; Sakata, Y; Yoshimori, K | 1 |
| Fukuoka, M; Hasegawa, K; Kimura, M; Kurita, Y; Kuriyama, T; Motomiya, M; Nakabayashi, T; Negoro, S; Niitani, H; Suzuki, A | 1 |
57 review(s) available for irinotecan and Carcinoma, Small Cell
| Article | Year |
|---|---|
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm; Drug Therapy, Combination; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Tegafur | 2020 |
[Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Creutzfeldt-Jakob Syndrome; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Phosphopyruvate Hydratase; Prostate; Prostatic Neoplasms; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
[A case of gastric small cell carcinoma with liver and lymph node metastases responding to CPT-11 plus CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
Primary combined small cell carcinoma and squamous cell carcinoma of the oropharynx with special reference to EGFR status of small cell carcinoma component: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; ErbB Receptors; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oropharyngeal Neoplasms; Otorhinolaryngologic Surgical Procedures | 2017 |
[A Case of Primary Poorly Differentiated/Small Cell Carcinoma of the Breast in a Patient with Von Recklinghausen's Disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neurofibromatosis 1 | 2016 |
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2010 |
Irinotecan in the treatment of small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Survival Rate | 2001 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
[Randomized controlled trials in Japan--lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2002 |
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic | 2002 |
Camptothecin and taxane regimens for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Small Cell; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Irinotecan plus cisplatin in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2002 |
Limited stage small cell lung cancer: treatment and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Treatment Outcome | 2003 |
Chemotherapy for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan | 2003 |
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Celecoxib; Cisplatin; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2003 |
Progress in treatment of small-cell lung cancer: role of CPT-11.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors | 2003 |
Chemotherapy of small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2004 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
[A case of gastric metastasis of small cell cancer of the lung, regression of the gastric lesion after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Fatal Outcome; Gastroscopy; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Stomach Neoplasms | 2004 |
Small-cell lung cancer: current therapy and novel agents.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis | 2005 |
[Treatment of small cell lung cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis | 2005 |
Evolving role of irinotecan in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms | 2003 |
Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Patient Compliance; Quality of Life | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2007 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
[Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glycosides; Humans; Irinotecan; Lung Neoplasms; Male; Methylnitrosourea; Middle Aged; Taxoids; Treatment Outcome | 2007 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
New antineoplastic agents in lung cancer 1988-1993.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Teniposide; Vinblastine; Vinorelbine | 1995 |
[Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Quality Control | 1996 |
[Chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Paclitaxel | 1996 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
[Small-cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
Extensive small-cell lung cancer: a treatment overview.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2000 |
Irinotecan in small-cell lung cancer--Japanese trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
Topoisomerase I targeting agents in small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; DNA Topoisomerases, Type I; Humans; Irinotecan; Lung Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors | 2001 |
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
Irinotecan in small-cell lung cancer: the US experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate; United States | 2001 |
Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids | 2001 |
Irinotecan: summary and future directions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Forecasting; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; United States | 2001 |
Current status of irinotecan in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2001 |
New state of the art in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate | 2001 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Role of topoisomerase I inhibitors in small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
Irinotecan therapy for small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; United States | 2002 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
[Irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2002 |
[New treatment strategy for stage III non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy; Taxoids; Treatment Outcome; Vinblastine | 2002 |
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
[DNA topoisomerase inhibitor].
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan | 1992 |
81 trial(s) available for irinotecan and Carcinoma, Small Cell
| Article | Year |
|---|---|
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2014 |
A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Protective Agents; Treatment Outcome | 2014 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2008 |
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2008 |
Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 2009 |
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Topoisomerase I Inhibitors | 2010 |
Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2011 |
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Platelet-Derived Growth Factor; Proportional Hazards Models; Vascular Endothelial Growth Factor A | 2011 |
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins | 2012 |
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Topics: Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2012 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Thrombocytopenia | 2002 |
Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2002 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2003 |
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2003 |
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.
Topics: Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Neutropenia; Sodium Bicarbonate; Survival Analysis; Treatment Outcome; Water | 2004 |
A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiography; Thrombocytopenia; Treatment Outcome | 2004 |
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Topoisomerase I Inhibitors | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome | 2005 |
A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 2005 |
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome | 2005 |
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2006 |
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2006 |
Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Disease Progression; Dose Fractionation, Radiation; Esophagitis; Feasibility Studies; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Thrombocytopenia; Treatment Outcome | 2006 |
A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Prospective Studies; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Radiotherapy; Recurrence; Time Factors; Treatment Outcome | 2006 |
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome | 2006 |
A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2007 |
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2006 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2007 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 2007 |
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2008 |
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2007 |
A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2008 |
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy | 2008 |
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2008 |
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan | 2008 |
Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia | 2008 |
Chemotherapy for brain metastases in small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cranial Irradiation; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2008 |
Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2007 |
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 1995 |
[Pilot study of irinotecan in refractory small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1995 |
Clinical studies of irinotecan alone and in combination with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1994 |
High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Spectrophotometry, Infrared | 1995 |
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis | 1998 |
[Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1998 |
Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemoglobins; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count | 1999 |
Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1999 |
[Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |
Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2000 |
Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel | 2000 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2002 |
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Evaluation; Drug Resistance; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome | 1992 |
[Advances in lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1992 |
[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1991 |
98 other study(ies) available for irinotecan and Carcinoma, Small Cell
| Article | Year |
|---|---|
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
[A Case of Small Cell Carcinoma of the Pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2019 |
Heterogenous chemosensitivity of a panel of organoid lines derived from small cell neuroendocrine carcinoma of the uterine cervix.
Topics: Antineoplastic Agents; Carboxylic Ester Hydrolases; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Catalysis; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Irinotecan; Organoids; Uterine Cervical Neoplasms | 2021 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms | 2014 |
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evidence-Based Medicine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Patient Selection; Platinum Compounds; Positron-Emission Tomography | 2013 |
Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Male; Prognosis; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Topics: Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Indoles; Irinotecan; Middle Aged; Piperazines; Proto-Oncogene Proteins c-met; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur | 2015 |
KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.
Topics: Acetylation; Animals; Antineoplastic Agents, Alkylating; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Gene Deletion; Gene Expression Profiling; Genes, Tumor Suppressor; Heterografts; Histone Acetyltransferases; Histones; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Protein Processing, Post-Translational; RNA Interference; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering | 2015 |
Long-term survival in small-cell carcinoma of the endometrium with liver and brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Endometrial Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms | 2016 |
Successful Multidisciplinary Therapy for Small Cell Carcinomas Arising from the Extrahepatic Bile Duct.
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Carcinoma, Small Cell; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Common Bile Duct; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Treatment Outcome | 2015 |
[Lymph Node Recurrence of Small Cell Carcinoma of the Extrahepatic Bile Ducts Effectively Treated with Cisplatin plus Irinotecan Chemotherapy - Report of a Case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Treatment Outcome | 2016 |
Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
[CR obtained by CPT-11 and CDDP combination-therapy in a small-cell lung-cancer patient through effective pharmaceutical care].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Radiography; Remission Induction; Time Factors | 2008 |
[A case of small cell carcinoma of the ureter].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Irinotecan; Male; Ureteral Neoplasms | 2008 |
[A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Differentiation; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatal Outcome; Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Treatment Failure | 2008 |
In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Taxoids; Xenograft Model Antitumor Assays | 2008 |
[CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Esophagoscopy; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Tomography, X-Ray Computed | 2009 |
[A case of superficial small cell carcinoma of the esophagus].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male | 2009 |
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Neoplasm Recurrence, Local; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Spinal Puncture; Treatment Outcome | 2009 |
Small cell carcinoma of the breast.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2009 |
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
Use of irinotecan for treatment of small cell carcinoma of the prostate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Therapy, Combination; Humans; Irinotecan; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Subrenal Capsule Assay | 2011 |
[A case of small cell carcinoma of esophagus treated by chemotherapy with CDDP plus CPT-11 and radiotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Irinotecan; Lymphatic Metastasis | 2010 |
Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Small Cell; Female; Fever; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Neutropenia; Renal Dialysis; Treatment Outcome | 2011 |
Esophageal small-cell carcinoma with syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Fatal Outcome; Humans; Hyponatremia; Inappropriate ADH Syndrome; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Paraneoplastic Endocrine Syndromes | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Everolimus; Female; Humans; Immunosuppressive Agents; Irinotecan; Liposomes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Sirolimus; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Chemotherapy-mediated tumor regression in a patient with stage IV stomach small cell cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of paraneoplastic syndrome improved following chemoradiotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Gait Ataxia; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Polyneuropathy; Paresthesia; Radiotherapy, Adjuvant; Treatment Outcome | 2003 |
Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Male; Microscopy, Confocal; Middle Aged; Prodrugs; Topoisomerase I Inhibitors | 2003 |
[Chemotherapy for small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2004 |
Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.
Topics: Antibiotics, Antitubercular; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Interactions; Glucuronates; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mycobacterium avium-intracellulare Infection; Rifampin; Tuberculosis, Pulmonary | 2004 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Complete response of brain metastases to irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Esophageal Neoplasms; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Parotid Neoplasms | 2005 |
[A young patient with invasive small cell carcinoma of the urinary bladder: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Drug Administration Schedule; Female; Humans; Hysterectomy; Irinotecan; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2005 |
A long-term survival case of small cell lung cancer in an HIV-infected patient.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed | 2005 |
[Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Kidney Diseases; Lung Neoplasms; Male | 2005 |
Irinotecan (CPT-11) combined with cisplatin for small cell carcinoma of the nasal cavity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Nasal Cavity; Neoadjuvant Therapy; Nose Neoplasms | 2006 |
[A case of small cell carcinoma of the stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Rupture, Spontaneous; Stomach Neoplasms; Stomach Rupture | 2005 |
A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Male; Tomography, X-Ray Computed | 2005 |
The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
Topics: Anthracyclines; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms | 2006 |
[A case of small-cell lung cancer responding remarkably to CPT-11 and CDDP combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cranial Irradiation; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Pleural Effusion, Malignant; Remission Induction; Tomography, X-Ray Computed | 2006 |
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
[Is small cell lung cancer an orphan disease?].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
[Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Pneumonectomy | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Irinotecan; Male; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2006 |
Fractionated administration of irinotecan and cisplatin in Japanese patients with extensive-stage-disease small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Humans; Irinotecan; Japan; Lung Neoplasms; Salvage Therapy; Sample Size; Time Factors | 2006 |
[A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms | 2006 |
[A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
[Small cell carcinoma of the urinary bladder treated with neo-adjuvant cp chemotherapy (CPT-11 and CDDP): a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Male; Urinary Bladder Neoplasms | 2007 |
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines | 2007 |
[A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Female; Genetic Markers; Genetic Variation; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neutropenia; Risk | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
[A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Routes; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Oxonic Acid; Stomach Neoplasms; Survivors; Tegafur | 2007 |
A case of small cell carcinoma of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Piperidines | 2007 |
Isolated metastasis of lung cancer to the thyroid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Small Cell; CD56 Antigen; Chemotherapy, Adjuvant; Chromogranin A; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Thyroid Neoplasms | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
[A case of small cell carcinoma of the esophagus with remarkable response to chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Remission Induction | 2007 |
[Carboplatin and CPT-11 chemotherapy in a hemodialysis patient with small-cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Radiosurgery; Time Factors; Tomography, X-Ray Computed | 2008 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Topics: Amidohydrolases; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Thymidylate Synthase | 2008 |
Small cell carcinoma of the extrahepatic bile duct diagnosed with EUS-FNA and effectively treated with chemoradiation.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Biopsy, Fine-Needle; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Therapy, Combination; Endosonography; Humans; Irinotecan; Male | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 1995 |
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
Topics: Antineoplastic Agents; Camptothecin; Carbazoles; Carcinoma, Small Cell; Cell Nucleus; Drug Resistance; Glucosides; Humans; In Vitro Techniques; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Humans; Injections, Intraperitoneal; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1993 |
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carbazoles; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cell Survival; Cisplatin; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Glucosides; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
[Small-cell lung cancer and subacute sensory neuropathy in a patient positive for the anti-Hu antigen].
Topics: Acute Disease; Antibodies, Anti-Idiotypic; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Biomarkers, Tumor; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Diseases | 1996 |
Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1997 |
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
[Pilot study of cisplatin, ifosfamide and irinotecan (CPT-11) with granulocyte colony-stimulating factor support (CIC-regimen) in relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects | 1998 |
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 1998 |
Successful clinical response to irinotecan in desmoplastic round blue cell tumor.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Desmin; Female; Humans; Irinotecan; Male; Prognosis; Treatment Outcome | 1999 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Camptosar plus cisplatin increase survival in small-cell lung cancer study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Radiosurgery; Radiotherapy, Adjuvant; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
[A case of small cell carcinoma of esophagus successfully treated by chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged | 2001 |
In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Thiazoles; Thiazolidinediones; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |
[A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged | 2001 |
Lung cancer--time to move on from chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Smoking; Survival Rate | 2002 |
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Survival; Cisplatin; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Formazans; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Tetrazolium Salts; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Irinotecan in small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Glucuronosyltransferase; Irinotecan; Lung Neoplasms; Polymorphism, Genetic; Prodrugs | 2002 |
[Irinotekan in spread small cell lung cancer. More studies are required to change the practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2002 |
[Small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Radiotherapy, Adjuvant; Treatment Outcome | 2002 |
[An early phase II study of CPT-11 in primary lung cancer].
Topics: Adenocarcinoma; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 1991 |